Results 31 to 40 of about 7,313 (199)

ESKALE study, a French real-world study describing TRD patients with Esketamine nasal spray: final analysis

European Psychiatry, 2023
Introduction Treatment resistant depression (TRD) affects a substantial proportion of patients with depression and carries a large unmet need. Esketamine nasal spray (NS), in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin ...
L. Samalin, L. Mekaoui, M. Rotharmel, P. de Maricourt, M.-A. Codet, E. Gaudre Wattinne   +5 more
doaj   +1 more source

A Clinical Rationale for Assessing the Impact of Childhood Sexual Abuse on Adjunctive Subcutaneous Esketamine for Treatment-Resistant Depression

Frontiers in Psychiatry, 2021
Background: A history of child sexual abuse (CSA) is related to higher suicide rates and poor treatment outcomes in depressed adult patients. Twenty years after the first study investigating the effects of ketamine/esketamine on depression and suicide ...
Eduardo Jorge Muniz Magalhães, Luciana Maria Sarin, Lorena Catarina Del Sant, Ana Cecília Lucchese, Carolina Nakahira, Marco Aurélio Tuena, Camila Brito Puertas, Victor Augusto Rodovalho Fava, Rodrigo Simonini Delfino, Rodrigo Simonini Delfino, Juliana Surjan, Juliana Surjan, Matheus Souza Steglich, Matheus Souza Steglich, Matheus Ghossain Barbosa, Guilherme Abdo, José Alberto Del Porto, José Alberto Del Porto, Charles B. Nemeroff, Hugo Cogo-Moreira, Hugo Cogo-Moreira, Acioly Luiz Tavares Lacerda, Acioly Luiz Tavares Lacerda, Acioly Luiz Tavares Lacerda, Acioly Luiz Tavares Lacerda, Andrea Feijo Mello, Andrea Feijo Mello   +26 more
doaj   +1 more source

Administration of Nebulized Ketamine for Managing Acute Pain in the Emergency Department: A Case Series [PDF]

, 2020
Ketamine administration in sub-dissociative doses in the emergency department (ED) results in effective pain relief in patients with acute traumatic and non-traumatic pain, chronic pain, and opioid-tolerant pain.
Butt, Mahlaqa, Drapkin, Jefferson, Hossain, Rukhsana, Likourezos, Antonios, Masoudi, Aidin, Motov, Sergey   +5 more
core  

Are we repeating mistakes of the past? A review of the evidence for esketamine – CORRIGENDUM [PDF]

, 2021
It should be emphasised that Table 1 in the Analysis1 combines data from Phase 2 trials (including open-label and placebo-controlled trial periods) and Phase 3 trials (placebo-controlled efficacy studies, a maintenance of effect study and a long-term ...
Horowitz, Mark A, Moncrieff, Joanna
core  

Electroconvulsive therapy vs Esketamine among patients with Major Depressive Episode

European Psychiatry, 2023
Introduction Major depressive disorder is one of the most common and disabling mental disorders. More than 30% of individuals do not achieve remission after several trials of antidepressants and treatment-resistant depression (TRD) is associated with ...
M. D. R. D. R. F. D. A. Basto, O. Nombora, L. Santa Marinha, J. L. Simães, A. Horta   +4 more
doaj   +1 more source

Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression:A qualitative study [PDF]

, 2022
BACKGROUND: Ketamine and its enantiomer esketamine represent promising new treatments for treatment-resistant depression (TRD). Esketamine induces acute, transient psychoactive effects.
Breeksema, Joost J., Kamphuis, Jeanine, Kuin, Bouwe, Niemeijer, Alistair, Schimmel, Nina, Schoevers, Robert, van den Brink, Wim, Veraart, Jolien, Vermetten, Eric   +8 more
core   +2 more sources

Esketamine nasal spray compassionate use program in the Netherlands: An open label, multi-center cohort study in severe treatment-resistant depression

Journal of Affective Disorders Reports
Background: Esketamine, a N-methyl-d-aspartate (NMDA) receptor antagonist, used intranasally (IN), is applied as an antidepressant (AD) in treatment-resistant depressed (TRD) patients. Real-world studies with IN esketamine are still scarce.
Abel (K.A.J.) Busz, Emma (E.J.) Schmidt, Rob (R.H.S.) van den Brink, Karen (K.) Foeken, Marasha (M.) de Jong, Joost (J.B.C.) Mertens, Martijn (M.S.) van Noorden, Etienne (E.J.F.L.) Olivier, Koen (K.R.J.) Schruers, Sara (S.I.J.) Schutters, Joris (J.) van Son, Wessel (W.J.) Strootker, Harry (H.C.P.) Venema, Dieuwertje (D.A.) de Waardt, Jasper (J.B.) Zantvoord, Danielle (D.) Cath, Henricus (H.G.) Ruhe   +16 more
doaj   +1 more source

Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review [PDF]

, 2020
This narrative review aims to provide an overview of the current literature on thepharmacology, safety, efficacy and tolerability of intranasal esketamine, the S-enantiomerof ketamine, for the treatment of treatment-resistant depression (TRD).
Peterson, GM, Salahudeen, MS, Wright, CM
core   +2 more sources

Overcoming the myths of esketamine administration: different and not difficult

Frontiers in Psychiatry, 2023
Intranasal esketamine for treatment-resistant depression has been introduced and approved by the FDA and EMA in 2019 and 2020, respectively. Since then, the administration practices were found different among countries. Major depression has a high impact
Florian Buchmayer, Siegfried Kasper
doaj   +1 more source

Nowe leki w psychiatrii – kariprazyna, lurazydon, esketamina [PDF]

, 2021
Introduction: Invariably, the search for an “ideal drug” in psychiatry has been going for years, one that is safe and effective, prevents relapse and shows the least possible side effects.
Masiak, Jolanta, Masiak, Jolanta, Pożarowska, Kinga, Pożarowska, Kinga, Rudziński, Gracjan, Rudziński, Gracjan, Rusinek, Adam, Rusinek, Adam, Soroka, Ewelina, Soroka, Ewelina   +9 more
core   +2 more sources